新型杂芳基氟代烯烃作为治疗癌症尤其是转移性黑色素瘤的二酰甘油激酶（DGK）抑制剂
Novel Heteroaryl Fluoroalkenes as DGK Inhibitors for Treating Cancer, Particularly Metastatic Melanoma.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Aug 22;15(9):1433-1434. doi: 10.1021/acsmedchemlett.4c00409. eCollection 2024 Sep 12.
Abstract
Provided herein are novel heteroaryl fluoroalkenes as DGK inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, particularly metastatic melanoma, and processes for preparing such compounds.
摘要
本文提供了作为二酰甘油激酶（DGK）抑制剂的新型杂芳基氟代烯烃、药物组合物、此类化合物在治疗癌症尤其是转移性黑素瘤中的用途以及制备此类化合物的方法。
相似文献
1
Novel Heteroaryl Fluoroalkenes as DGK Inhibitors for Treating Cancer, Particularly Metastatic Melanoma.新型杂芳基氟代烯烃作为治疗癌症尤其是转移性黑色素瘤的二酰甘油激酶（DGK）抑制剂
ACS Med Chem Lett. 2024 Aug 22;15(9):1433-1434. doi: 10.1021/acsmedchemlett.4c00409. eCollection 2024 Sep 12.
2
Novel Tricyclic Triazolo Compounds as DGK Inhibitors for Treating Metastatic Melanoma.新型三环三唑化合物作为治疗转移性黑色素瘤的二酰甘油激酶（DGK）抑制剂
ACS Med Chem Lett. 2025 Jul 15;16(8):1492-1493. doi: 10.1021/acsmedchemlett.5c00401. eCollection 2025 Aug 14.
3
Novel Bicyclic DGK Inhibitors for Treating Metastatic Melanoma.用于治疗转移性黑色素瘤的新型双环二酰甘油激酶抑制剂
ACS Med Chem Lett. 2025 Apr 2;16(5):728-729. doi: 10.1021/acsmedchemlett.5c00164. eCollection 2025 May 8.
4
Novel Bicyclic Amines as CDK2 Inhibitors for Treating Metastatic Breast Cancer or Metastatic Lung Cancer.新型双环胺类化合物作为治疗转移性乳腺癌或转移性肺癌的细胞周期蛋白依赖性激酶2（CDK2）抑制剂
ACS Med Chem Lett. 2025 Jan 16;16(2):198-199. doi: 10.1021/acsmedchemlett.5c00005. eCollection 2025 Feb 13.
5
Novel Compounds as CDK2 Inhibitors for Treating Cancer.新型化合物作为治疗癌症的CDK2抑制剂
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
6
Pyrrolopyrazine Compounds as ERK5 Inhibitors for Treating Cancer.作为用于治疗癌症的细胞外信号调节激酶5（ERK5）抑制剂的吡咯并吡嗪化合物
ACS Med Chem Lett. 2024 Dec 11;16(1):16-17. doi: 10.1021/acsmedchemlett.4c00580. eCollection 2025 Jan 9.
7
Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.作为用于治疗癌症的CD73抑制剂的新型双环杂环化合物。
ACS Med Chem Lett. 2024 Dec 4;16(1):10-11. doi: 10.1021/acsmedchemlett.4c00565. eCollection 2025 Jan 9.
8
Novel Indazole Compounds as PKMYT1 Kinase Inhibitors for Treating Cancer.新型吲唑化合物作为治疗癌症的PKMYT1激酶抑制剂
ACS Med Chem Lett. 2024 Oct 12;15(11):1810-1811. doi: 10.1021/acsmedchemlett.4c00486. eCollection 2024 Nov 14.
9
Novel Substituted Benzimidazole Compounds as TLR9 Inhibitors for Treating Fibrotic Diseases, Particularly Idiopathic Pulmonary Fibrosis.新型取代苯并咪唑化合物作为用于治疗纤维化疾病，特别是特发性肺纤维化的TLR9抑制剂
ACS Med Chem Lett. 2024 Oct 16;15(11):1804-1805. doi: 10.1021/acsmedchemlett.4c00473. eCollection 2024 Nov 14.
10
Novel Piperidinylpyridinylcarbonitrile Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer.新型哌啶基吡啶基甲腈衍生物作为治疗癌症的QPCT和QPCTL抑制剂
ACS Med Chem Lett. 2025 Apr 14;16(5):758-759. doi: 10.1021/acsmedchemlett.5c00198. eCollection 2025 May 8.
引用本文的文献
1
Novel Bicyclic DGK Inhibitors for Treating Metastatic Melanoma.用于治疗转移性黑色素瘤的新型双环二酰甘油激酶抑制剂
ACS Med Chem Lett. 2025 Apr 2;16(5):728-729. doi: 10.1021/acsmedchemlett.5c00164. eCollection 2025 May 8.
本文引用的文献
1
The cellular and molecular targets of natural products against metabolic disorders: a translational approach to reach the bedside.天然产物针对代谢紊乱的细胞和分子靶点：通向临床应用的转化方法。
MedComm (2020). 2024 Jul 24;5(8):e664. doi: 10.1002/mco2.664. eCollection 2024 Aug.
2
Lipid switches in the immunological synapse.免疫突触中的脂质开关
J Biol Chem. 2024 Jul;300(7):107428. doi: 10.1016/j.jbc.2024.107428. Epub 2024 May 30.
3
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity.挖掘 KRAS 抑制对肿瘤免疫的治疗意义。
Cancer Cell. 2024 Mar 11;42(3):338-357. doi: 10.1016/j.ccell.2024.02.012.
4
Diacylglycerol kinases: A look into the future of immunotherapy.二酰甘油激酶：免疫疗法的未来展望。
Adv Biol Regul. 2024 Jan;91:100999. doi: 10.1016/j.jbior.2023.100999. Epub 2023 Nov 2.
Zotero 插件